Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3526 |
|
| Actual shortage: | 229 (6%) | |
| Anticipated shortage: | 3 (0%) | |
| Avoided shortage: | 11 (0%) | |
| Resolved: | 3283 (93%) | |
Discontinuation Reports |
366 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 342 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
32 (13%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-KETOCONAZOLE | 200MG | TABLET | Resolved | 2020-08-12 | 2020-09-01 | 122065 |
| APO-KETOROLAC | 10MG | TABLET | Resolved | 2021-04-23 | 2021-05-17 | 137959 |
| APO-KETOROLAC | 10MG | TABLET | Resolved | 2024-03-01 | 2024-04-19 | 221084 |
| APO-KETOROLAC | 10MG | TABLET | Resolved | 2024-03-01 | 2024-04-19 | 221102 |
| APO-KETOROLAC | 10MG | TABLET | Resolved | 2025-02-13 | 2025-03-21 | 250316 |
| APO-KETOROLAC INJECTABLE | 30MG | SOLUTION | Actual shortage | 2017-08-16 | 2017-10-05 | 19595 |
| APO-KETOTIFEN - SYR 1MG/5ML | 1MG | SYRUP | Actual shortage | 2017-08-13 | 2017-10-05 | 19024 |
| APO-LABETALOL | 100MG | TABLET | Resolved | 2022-09-30 | 2022-10-14 | 170804 |
| APO-LABETALOL | 200MG | TABLET | Resolved | 2023-02-23 | 2023-03-02 | 185489 |
| APO-LABETALOL | 100MG | TABLET | Resolved | 2023-06-16 | 2023-07-21 | 195069 |
| APO-LABETALOL | 200MG | TABLET | Resolved | 2023-07-13 | 2023-07-21 | 198511 |
| APO-LABETALOL | 200MG | TABLET | Resolved | 2023-11-10 | 2024-01-05 | 209964 |
| APO-LABETALOL | 100MG | TABLET | Resolved | 2023-12-01 | 2024-01-05 | 212359 |
| APO-LABETALOL | 200MG | TABLET | Resolved | 2024-06-20 | 2024-06-28 | 231030 |
| APO-LABETALOL | 100MG | TABLET | Resolved | 2024-09-27 | 2024-10-25 | 238826 |
| APO-LABETALOL | 200MG | TABLET | Resolved | 2024-09-27 | 2024-11-29 | 238829 |
| APO-LABETALOL | 100MG | TABLET | Resolved | 2017-08-13 | 2021-01-11 | 19105 |
| APO-LABETALOL | 200MG | TABLET | Resolved | 2017-08-13 | 2021-01-11 | 19108 |
| APO-LAMIVUDINE | 150MG | TABLET | Resolved | 2017-03-11 | 2017-05-16 | 664 |
| APO-LAMIVUDINE | 300MG | TABLET | Resolved | 2017-07-11 | 2017-08-31 | 15271 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |